TSRA 32.22 Tessera Technologies $TSRA Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 12:29 PM

TSRA 32.22 Tessera Technologies $TSRA Hit a 52 week high of 32.22 Closing the day 09:44 at 32.22 +0.30 +0.94% With a day low of 31.78 and a total volume of 17,198.

TSRA Recent Posts: http://investorshangout.com/Tessera-Technolog...SRA-55695/

TSRA Tessera Technologies Recent Headline News

Surging Earnings Estimates Signal Good News for Tessera Technologies (TSRA) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:58AM CST
Tessera Technologies has decent short-term momentum and is seeing solid activity on the earnings estimate revision front for the coming quarter and year.
TSRA: 32.19 (+0.27)

Tessera Technologies and O-Film Announce Amended Transaction
Business Wire - Mon Nov 17, 6:01AM CST
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company"

announced that the Company and its wholly-owned subsidiary DigitalOptics Corporation (together with its subsidiaries, "DOC"

have agreed to close an amended definitive agreement (the "Agreement"

with Shenzhen O-Film Tech Co., LTD. ("Shenzhen O-Film," together with affiliates, collectively, "O-Film"

on December 2, 2014.
TSRA: 32.19 (+0.27)

Why Semiconductor Stocks Could Be Far From Dead
at Investor's Business Daily - Wed Nov 12, 3:50PM CST
What if there was a funeral and the dearly beloved, who was supposed to be dead, showed up in fine health? Something akin to that has happened in the chip space. The chip sector was supposed to be heading into an industrywide correction. After the...
TSRA: 32.19 (+0.27), MCHP: 43.30 (-0.06), NXPI: 74.21 (+0.48), AVGO: 88.01 (-1.00)

Axcelis Technologies (ACLS) Jumps: Stock Rises 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:04AM CST
Axcelis Technologies Inc. (ACLS) was a big mover last session, as the company saw its shares rise over 7% on the day.
TSRA: 32.19 (+0.27), RTEC: 9.05 (-0.11), MTSN: 2.69 (-0.04), ACLS: 2.17 (-0.02)

Tessera Technologies Beats on Q3 Earnings & Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:00PM CST
Tessera Technologies Inc. (TSRA) reported strong third-quarter 2014 earnings from continuing operations that jumped from a significant loss in the year-ago quarter and small profit in the previous quarter to sail past the Zacks Consensus Estimate.
AXTI: 2.40 (-0.05), CHTR: 154.02 (+1.92), TSRA: 32.18 (+0.26), SIMO: 21.62 (+0.41)

Tessera Technologies (TSRA) Upgraded From Hold to Buy
at The Street - Mon Nov 03, 8:55AM CST
Tessera Technologies (TSRA) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B+.
TSRA: 32.18 (+0.26)

Tessera posts 3Q profit
Automated Insights - Fri Oct 31, 4:04AM CDT
SAN JOSE, Calif. (AP) _ Tessera Technologies Inc. (TSRA) on Friday reported net income of $108.7 million in its third quarter.
TSRA: 32.17 (+0.25)

Tessera Technologies' (TSRA) CEO Tom Lacey on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 9:45PM CDT

TSRA: 32.17 (+0.25)

TESSERA TECHNOLOGIES
at Investor's Business Daily - Thu Oct 30, 6:13PM CDT
TESSERA TECHNOLOGIES (TSRA), a tech firm, said Q3 EPS grew to 87 cents from last year's Q3 per-share loss of 91 cents, topping by 7 cents. Sales surged 150.4% to $93.3 mil, topping views for $91.9 mil. Shares rose.
TSRA: 32.17 (+0.25)

Tessera guides above consensus
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 5:41PM CDT

TSRA: 32.17 (+0.25)

Tessera Technologies (TSRA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 3:55PM CDT

TSRA: 32.17 (+0.25)

Tessera beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:20PM CDT

TSRA: 32.17 (+0.25)

Tessera Technologies Announces Third Quarter 2014 Results
Business Wire - Thu Oct 30, 3:07PM CDT
--Recurring Revenue Increases 70% to $47.3 Million Year-Over-Year--
TSRA: 32.17 (+0.25)

Can Tessera Technologies' (TSRA) Earnings Surprise in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 4:40PM CDT
Tessera Technologies Inc. (TSRA) is slated to report third-quarter 2014 results on Oct 30.
AMKR: 6.77 (+0.38), TEL: 60.87 (-0.66), TSRA: 32.17 (+0.25), MELI: 132.84 (-1.78)

EMCORE Slumps: EMKR Falls 7.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 7:38AM CDT
EMCORE (EMKR) fell nearly 9% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down over 13% in the past one-month time frame.
EMKR: 5.16 (unch), COHU: 11.53 (-0.11), TSRA: 32.17 (+0.25), ACLS: 2.17 (-0.02)

Tessera Technologies to Report Third Quarter 2014 Results on Thursday, October 30
Business Wire - Tue Oct 14, 6:00AM CDT
Tessera Technologies, Inc. (NASDAQ:TSRA) ("Tessera" or the "Company"

will announce its financial results for the third quarter ended September 30, 2014 on Thursday, October 30, 2014, following the close of the market. The Company will host an earnings conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) that same day. During the call, senior management will review the Company's third quarter financial results and business outlook.
TSRA: 32.17 (+0.25)

Amkor Technology Announces Rulings in Tessera Proceedings
Business Wire - Mon Oct 13, 10:59AM CDT
Amkor Technology, Inc. (NASDAQ: AMKR) today announced two rulings in its long-running dispute with Tessera Technologies, Inc. related to a license agreement entered into in 1996 between Tessera and Amkor's predecessor. On October 10, 2014, the Patent Trial and Appeal Board at the United States Patent and Trademark Office, in an inter partes review proceeding, or IPR, ruled on our petition seeking cancellation of certain claims of U.S. Patent No. 6,046,076. In a two-one decision, the IPR board reversed its preliminary determination and denied Amkor's petition with respect to the most material claims. As previously reported, an arbitration panel has awarded Tessera royalties of $113 million plus interest, most of which relate to our alleged use of the '076 patent. The Superior Court for San Francisco County formally confirmed the arbitration panel's award on October 9.
AMKR: 6.77 (+0.38), TSRA: 32.17 (+0.25)

Amkor announces two rulings in dispute proceedings with Tessera
M2 - Mon Oct 13, 8:45AM CDT
A provider of outsourced semiconductor packaging and test services, Amkor Technology Inc (NASDAQ:AMKR) today declared two rulings in its dispute with Tessera Technologies Inc, regarding a license agreement signed in 1996 between Tessera and Amkor's predecessor.
AMKR: 6.77 (+0.38), TSRA: 32.17 (+0.25)

$128.3 Million Judgment Entered by California Court on Tessera's Arbitration Award Against Amkor
Business Wire - Fri Oct 10, 3:05PM CDT
Tessera Technologies, Inc. (NASDAQ: TSRA) ("Tessera" or the "Company"

announced today that a California state court confirmed Tessera, Inc.'s arbitration award and entered judgment of $128,335,504 plus post-judgment interest against Amkor Technology, Inc. ("Amkor"

, and that the U.S. Patent Office confirmed the patentability of key claims in a Tessera patent that Amkor had challenged in an inter partes review ("IPR"

proceeding. The patent was one of several at issue in the arbitration.
AMKR: 6.77 (+0.38), TSRA: 32.17 (+0.25)

First Week of TSRA November 22nd Options Trading
DividendChannel.com - Wed Oct 08, 9:52AM CDT
Investors in Tessera Technologies Inc saw new options begin trading this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TSRA options chain for the new November 22nd contracts and...
TSRA: 32.17 (+0.25)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....